Oryzon Genomics today announced the start of a collaboration with Schizophrenia Precision Medicine (SCZ) with researchers at Columbia University in New York, Dr. Joseph Gogos, Sander Markx and Jeffrey Lieberman
SETD1A is a key gene for susceptibility to the development of schizophrenia. The collaboration consists of two parts: one will deepen the preclinical characterization of the possible therapeutic action on SETD1A with LSD inhibitors. In the second part, an exhaustive functional psychometric characterization of individuals with mutations in the SETD1A gene will be performed. “With the information obtained, we want to lay the foundations for a further clinical study of precision psychiatry with the inhibitor LSD1 vafidemstat to treat the psychiatric disorders associated with SETD1A, ”Oryzon said in a press release.
Free webinars to invest
The Department of Investment Strategy Analysis conducts a series of free webinars to learn about the Spanish, European and American stocks we like best, as well as a webinar on technical indicators.
Vafidemstat is an inhibitor of LSD1 in phase II clinical development that has demonstrated a good safety profile and has been shown to be effective in reducing agitation and aggression in clinical trials in patients with Alzheimer’s disease, borderline personality disorder (BPD). ), attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Vafidemstat is currently being explored in two phase IIb clinical trials, one in BPD and the other in critically ill patients with Covid-19.. In the field of precision psychiatry, vafidemstat is also explored in Europe in patients with Phelan-McDermid syndrome, a variety of autism, which harbor a mutation in SHANK3.
The study’s lead investigator, Dr. Markx, said: “We are very excited to work with Oryzon in conducting a reference neuropsychiatric characterization study. This study will undoubtedly pave the way for one of the first precision psychiatric clinical trials., which will explore vadifemstat in psychiatric disorders associated with SETD1A deficiencies. ”
Dr. Gogos, a professor at Columbia University, said: “Following the enormous success of human psychiatric genetics, the goal of using the knowledge of genetic studies to identify drugs targeting disease-specific biological mechanisms is beginning to be available. The birth of this type of “precision treatment” is an interesting moment in the fight against psychiatric disorders. ”
Carlos Buesa, CEO of Oryzon, commented: “We are very excited to begin this revolutionary collaboration with researchers at the prestigious Columbia University with international renown in this field.Precision medicine can open a new way of understanding and treating CNS diseases. It has been proposed that epigenetic irregularity of histone methylation be an important mechanism at the origin of schizophrenia and autism. Vafidemstat is an experimental drug with a good safety profile and its clinical results so far suggest that it may have therapeutic potential in schizophrenia, so we are looking forward to starting this study. ”
Strong sectors and values to invest.
The investment strategy analysis department analyzes the strongest sectors and actions on the market.
Discover the most remarkable analyzes of our team, from a technical and fundamental point of view.
Corporate movements, currency developments and central bank policies will move markets a lot, as institutional investors will shift portfolios to higher or lower risk sectors.
Discover it here